By Fineline Cube 
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced a significant investment of BRL 6.4 billion (USD 1.09 billion) in the expansion of its manufacturing plant in Montes Claros, Brazil. The investment aims to increase production capacity for injectable drugs targeting obesity and other serious chronic diseases, positioning Novo Nordisk to better serve the Brazilian market.
Expansion Details and Impact
This substantial investment, one of the largest in Brazil’s pharmaceutical industry, is expected to significantly enhance the facility’s capacity. The expansion will include additional aseptic production processes, a new warehouse, and a state-of-the-art quality control laboratory. The facility will manufacture a variety of injectables, including GLP-1 medicines such as Ozempic and Wegovy, utilizing advanced and future-oriented technologies.
Timeline and Economic Benefits
The expansion has already commenced, with completion anticipated in 2028. Once complete, the project will create 600 new jobs, further supporting local economic development and establishing Novo Nordisk as a key player in Brazil’s growing pharmaceutical sector.-Fineline Info & Tech